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Clinicians perspective of the new pregnancy and lactation labeling final rule(PLLR): results from a FDA/ AAAAI survey Christina Chambers, PhD MPH 1 , and Jennifer A. Namazy, MD FAAAAI 2 ; 1 University of California, San Diego, La Jolla, CA, 2 Scripps Clinic, San Diego, CA. RATIONALE: In 2015, the FDA removed the letter category system (A,B,C,D or X) from the product label of all prescription drugs. The letter category system first established in 1979 was regarded as overly simplistic and misinterpreted as a grading system. A new PLLR format was created to better aid in presenting the available safety data. In an attempt to assess awareness, understanding and value of the new PLLR, a survey formed in collaboration between the AAAAI and the FDA was distributed among the membership of the AAAAI. METHODS: An online survey was sent to a random sample of the US membership of the AAAAI. The survey content consisted of questions addressing the following: demographics, awareness and use of the PLLR, understanding of the new PLLR format in example form, and the value of the new PLLR format. RESULTS: Of 1500 members who received an email survey, 184 (12%) completed the survey. Less than half of responders were aware that the pregnancy letter categories were replaced with a narrative summary. Most of the responders did not feel the new PLLR format was clear or concise, and almost all responders continued to use the pregnancy letter category system (A,B,C,D,or X) to make prescribing decisions. CONCLUSIONS: Inadequate management of chronic medical conditions during pregnancy can have profound effects on maternal and fetal health. [Wang-2016] . Exacerbation prevention strategies can include allergy testing and the usage of mite-impermeable encasings [Murray-2017] . Asthma exacerbations is one of the main causes of hospital-admissions, with 37.3% of asthmatic children admitted to hospital every year [Berry-2013] ($3,782/year/ child [Barrett-2014] ); dust mites can increase this risk [Wang-2009] . This study estimates the potential cost savings to US payors, should serology testing be performed in the total population of asthmatic children, and should interventions to reduce exposure to mites be in place for 5 years. METHODS: In 2016, there were 6,132,000 asthmatic children [CDCdata] and 1,876,392 mite-sensitized-asthmatics. The model simulated an intervention where all asthmatic children were screened with serology ($154 for 25 tests [CMS-data]), encasings were assigned to mite-sensitized individuals (not included in the cost calculations), with a 27% reduction in hospitalizations after intervention [Murray-2017] . The output, from payors perspective, were exacerbation-related hospitaladmission costs with and without intervention. RESULTS: Without intervention, mite-related hospital-admission costs were $ 15,951,152,031 in 5 years. Screening with serology all prevalent and incident (almost 500,000 incident cases per year [Winer-2012] ) asthmatic children once costed $1,270,390,384, leading to total savings to payors equal to $ 2,875,600,859 in 5 years. CONCLUSIONS: The proposed simulated intervention, screening with serology testing all asthmatic children and assigning beddings to the mitesensitized ones, could hypothetically lead to substantial cost savings to US payors due to reduced hospital-admissions.
